These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24237124)

  • 1. Post-Therasense inequitable conduct: a pharmaceutical perspective.
    Carson PA; Forchheimer D; Draper DN
    Pharm Pat Anal; 2013 Jul; 2(4):467-79. PubMed ID: 24237124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
    Genieser LH; McCann CE
    Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The shadow of inequitable conduct in the US patent application.
    Chang BC; Wang SJ
    Hum Vaccin Immunother; 2016 May; 12(5):1318-20. PubMed ID: 26810884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How would patent reform legislation in the United States impact the pharmaceutical industry?
    Williams AW
    Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-to-invent versus first-to-file: impact of the AIA.
    Rachinsky T; Sullivan C; Ghosh S; Resnick DS; Burton C; Armstrong M; Hanish JP; Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):353-9. PubMed ID: 25291309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Misleading data in pharmaceutical and biological patent specifications: best mode after the America Invents Act.
    Laporte C; Deneke CC; Banks D
    Pharm Pat Anal; 2015; 4(4):247-51. PubMed ID: 26174564
    [No Abstract]   [Full Text] [Related]  

  • 8. The extraterritoriality of US patents on the pharmaceutical industry.
    Park H
    Pharm Pat Anal; 2014 Sep; 3(5):491-8. PubMed ID: 25374318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent owner options for correcting errors in US patents after grant.
    Armstrong M
    Pharm Pat Anal; 2014 Sep; 3(5):499-508. PubMed ID: 25374319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical patent law: the Canadian perspective.
    Aumand L; Norman J
    Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The America Invents Act: summarizing the statute.
    Calkins J
    Pharm Pat Anal; 2012 Mar; 1(1):13-6. PubMed ID: 24236707
    [No Abstract]   [Full Text] [Related]  

  • 12. The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry.
    Burton CA; Margonis LE
    Pharm Pat Anal; 2013 Mar; 2(2):177-80. PubMed ID: 24237023
    [No Abstract]   [Full Text] [Related]  

  • 13. Uncharted territories of the patent-restoration due-diligence challenge.
    Gaudry KS
    Food Drug Law J; 2011; 66(1):121-38, iii. PubMed ID: 24505850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent term extensions: issues, challenges and implications for pharmaceuticals.
    Clark L; Beadle D
    Pharm Pat Anal; 2012 Sep; 1(4):427-35. PubMed ID: 24236881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilski: assessing the impact of a newly invigorated patent-eligibility doctrine on the pharmaceutical industry and the future of personalized medicine.
    Holman CM
    Curr Top Med Chem; 2010; 10(18):1937-49. PubMed ID: 20615185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
    Leary TB
    J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1).
    Tsao R; Hurley EA
    Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
    Tancer RS
    Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotech patents and the inequitable conduct doctrine.
    Michael A
    Nat Biotechnol; 2006 Oct; 24(10):1219-21. PubMed ID: 17033655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.